Want to see ONCY full AI Analyst Report?
Top Page
Oncolytics Biotech
(NASDAQ:ONCY)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.54
▼(-36.86% Downside)
Action:Reiterated
Date:09/29/26
The score is weighed down primarily by weak financial performance (no revenue, widening losses, persistent cash burn, and negative equity) and bearish technicals (below major moving averages with negative MACD). Pipeline/regulatory corporate updates provide some support, but the Nasdaq bid-price noncompliance and lack of valuation/dividend support keep the overall profile low.
Positive Factors
Regulatory pathway clarity
FDA alignment on a potential registrational path gives REO 033 a clearer development framework and could reduce regulatory uncertainty. If interim results are supportive, the planned Part B expansion may provide a more direct route toward accelerated and eventual full approval.
Negative Factors
No commercial revenue
The absence of reported revenue means Oncolytics has not yet established a commercial cash-generating business, while widening losses show continued dependence on development financing. This limits internal funding capacity and leaves results highly dependent on clinical progress.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory pathway clarity
FDA alignment on a potential registrational path gives REO 033 a clearer development framework and could reduce regulatory uncertainty. If interim results are supportive, the planned Part B expansion may provide a more direct route toward accelerated and eventual full approval.
Read all positive factors
Oncolytics Biotech (ONCY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$71.02M
Dividend YieldN/A
Average Volume (3M)1.03M
Price to Earnings (P/E)―
Beta (1Y)1.42
Revenue GrowthN/A
EPS Growth2.05%
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.34
Shares Outstanding127,510,506
10 Day Avg. Volume950,056
30 Day Avg. Volume1,026,362
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)-22.05
Price to Sales (P/S)0.00
P/FCF Ratio-5.71
Enterprise Value/Market Cap1.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.90
Forecast
1Y Price Target
$5.00Price Target Upside481.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.34
Revenue Forecast (FY)N/A
Oncolytics Biotech Business Overview & Revenue Model
Company Description
Oncolytics Biotech Inc. is a biopharmaceutical firm in its development stage, dedicated to researching and creating medicinal therapies for cancer. The company's primary asset is pelareorep, an immunotherapeutic agent administered intravenously to...
How the Company Makes Money
Oncolytics Biotech does not have publicly established, consistent commercial product revenue because its lead program is in clinical development and has not been broadly commercialized. As a clinical-stage biotech, the company’s operations are typ...
Oncolytics Biotech Earnings Call Summary
Earnings Call Date:May 14, 2025
(Q1-2025)
| % Change Since: |
Next Earnings Date:Oct 30, 2026
Earnings Call Sentiment Positive
The earnings call reflects a strong positive sentiment with significant advancements in clinical data and strategic financial moves. The highlights, particularly in clinical trial progress and promising data across several cancer types, outweigh the challenges such as the ongoing CEO search and reduced R&D spending.Positive Updates
Clinical Data Exceeds Expectations
Oncolytics Biotech's clinical data for pelareorep continues to exceed expectations, particularly in difficult-to-treat malignancies such as pancreatic cancer, breast cancer, and anal carcinoma.
Negative Updates
Ongoing CEO Search
The search for a new CEO is still ongoing, indicating a potential leadership gap in the interim period.
Read all updates
Q1-2025 Updates
Positive
Negative
Clinical Data Exceeds Expectations
Oncolytics Biotech's clinical data for pelareorep continues to exceed expectations, particularly in difficult-to-treat malignancies such as pancreatic cancer, breast cancer, and anal carcinoma.
Read all positive updates
Company Guidance
During the first quarter conference call for Oncolytics Biotech in 2025, the company provided guidance on several key metrics related to the development of their cancer therapeutic, pelareorep (pela). They reported cash and cash equivalents of $15.3 million, which is expected to provide financial runway through the third quarter of 2025. Net cash used in operating activities was $6.5 million, a decrease from $7.5 million in the same period last year. General and administrative expenses remained consistent at $3 million, while research and development expenses decreased to $4.1 million from $5.7 million in Q1 2024. The net loss for the quarter was $6.7 million, or $0.08 per share, compared to $6.9 million or $0.09 per share in the previous year. The company also announced a $20 million share purchase agreement with Alumni Capital to extend their financial runway. Oncolytics is advancing their clinical trials, particularly focusing on breast and pancreatic cancer, with promising efficacy data from randomized Phase 2 studies and plans for future registrational opportunities.Oncolytics Biotech Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
28
Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -37.96M | -28.66M | -25.45M | -25.17M | -19.55M | -25.78M |
| Net Income | -38.21M | -28.76M | -22.79M | -20.92M | -18.30M | -26.30M |
Balance Sheet | ||||||
| Total Assets | 7.67M | 10.40M | 20.19M | 38.82M | 37.33M | 45.88M |
| Cash, Cash Equivalents and Short-Term Investments | 4.12M | 7.14M | 15.94M | 34.91M | 32.14M | 41.26M |
| Total Debt | 448.00K | 772.51K | 1.06M | 423.00K | 373.00K | 655.00K |
| Total Liabilities | 13.84M | 15.62M | 14.20M | 11.26M | 10.83M | 9.78M |
| Stockholders Equity | -6.17M | -5.21M | 5.98M | 27.56M | 26.50M | 36.10M |
Cash Flow | ||||||
| Free Cash Flow | -28.93M | -20.12M | -20.06M | -21.45M | -17.25M | -22.72M |
| Operating Cash Flow | -28.92M | -20.11M | -19.88M | -21.44M | -17.21M | -22.43M |
| Investing Cash Flow | -12.29K | -6.00K | -174.00K | 15.24M | -15.03M | -286.00K |
| Financing Cash Flow | 22.25M | 14.12M | 5.03M | 24.12M | 8.99M | 33.02M |
Oncolytics Biotech Technical Analysis
Negative
0.86
Price Trends
0.76
Negative
0.82
Negative
0.90
Negative
Market Momentum
-0.06
Positive
23.94
Positive
13.02
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ONCY, the sentiment is Negative. The current price of 0.86 is above the 20-day moving average (MA) of 0.68, above the 50-day MA of 0.76, and below the 200-day MA of 0.90, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 23.94 is Positive, neither overbought nor oversold. The STOCH value of 13.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ONCY.
Oncolytics Biotech Risk Analysis
Oncolytics Biotech disclosed 68 risk factors in its most recent earnings report. Oncolytics Biotech reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Oncolytics Biotech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $180.12M | 1.02 | 72.96% | 6.79% | -100.00% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $310.44M | -4.92 | -75.35% | ― | 220.34% | 55.73% | |
46 Neutral | $24.35M | -0.56 | -102.99% | ― | ― | -28.83% | |
45 Neutral | $71.02M | -2.31 | 1020.21% | ― | ― | 2.05% | |
45 Neutral | $249.93M | -1.07 | -87.95% | ― | -100.00% | 14.08% | |
42 Neutral | $95.16M | -8.03 | 44.67% | ― | -96.72% | -253.97% |
* Healthcare Sector Average
ONCY
Oncolytics Biotech
0.56
-0.61
-52.39%
ATOS
Atossa Therapeutics
2.44
-13.31
-84.51%
ORMP
Oramed Pharm
4.33
2.08
92.79%
ATRA
Atara Biotherapeutics
9.48
-5.56
-36.97%
ZNTL
Zentalis Pharmaceuticals
2.64
1.02
62.96%
PRLD
Prelude Therapeutics
3.89
2.64
211.20%
Oncolytics Biotech Corporate Events
Business Operations and StrategyProduct-Related Announcements
Oncolytics Biotech Highlights Pelareorep’s Tumor-Activating Potential
Positive
Sep 29, 2026
On September 29, 2026, Oncolytics Biotech announced that data published in the Proceedings of the National Academy of Sciences showed its investigational immunotherapy pelareorep can convert immunologically inactive hepatocellular carcinoma tumors...
Business Operations and StrategyRegulatory Filings and Compliance
Oncolytics Advances Pelareorep Trial, Gains FDA Alignment
Positive
Sep 28, 2026
On September 28, 2026, Oncolytics Biotech reported operational progress in its randomized REO 033 study of pelareorep for second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer, with nearly all Part A clinical sites now activat...
Business Operations and StrategyProduct-Related Announcements
Oncolytics Biotech Reports Positive Pelareorep Preclinical Results
Positive
Sep 10, 2026
On September 10, 2026, Oncolytics Biotech announced positive preclinical results from a study combining its investigational immunotherapy pelareorep with a pan-RAS inhibitor in a RAS-driven colorectal cancer model. During an initial intensive dosi...
Business Operations and StrategyRegulatory Filings and Compliance
Oncolytics Biotech gains FDA alignment on REO 033 trial
Positive
Aug 18, 2026
On August 18, 2026, Oncolytics Biotech Inc. reported it had received written feedback from the U.S. Food and Drug Administration on the design of a potential pivotal Part B expansion of its REO 033 study in second-line RAS-mutant, microsatellite s...
Delistings and Listing ChangesRegulatory Filings and Compliance
Oncolytics Biotech Faces Nasdaq Minimum Bid Price Noncompliance
Negative
Jul 24, 2026
On July 20, 2026, Oncolytics Biotech disclosed that it received a notice from Nasdaq indicating its shares had traded below $1.00 for 30 consecutive business days, putting the company out of compliance with the exchange’s minimum bid price r...
Business Operations and StrategyRegulatory Filings and Compliance
Oncolytics Biotech gains FDA Fast Track for pelareorep
Positive
Jul 20, 2026
On July 20, 2026, Oncolytics Biotech announced that the U.S. Food and Drug Administration granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for patients with inoperable, locally recurrent or metastatic squamou...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Oncolytics Biotech advances REO 033 colorectal cancer program
Positive
Jul 13, 2026
On July 13, 2026, Oncolytics Biotech reported clinical and regulatory progress for its REO 033 randomized controlled trial of pelareorep plus FOLFIRI and bevacizumab in second-line RAS-mutant, microsatellite stable metastatic colorectal cancer, bu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.